Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

225Ac-RYZ-801

Generic Name: 225Ac-RYZ-801

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC

Phase 1

Recruiting

Posted: 2024/12/10

Sponsor:RayzeBio, Inc.

ID:NCT06726161

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Radiopharmaceuticals: The Next Frontier in Precision Oncology as Big Pharma Competes for Market Share

2 months ago

Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy